NCM client, Angel CoFund, has invested in Oxford Drug Design Limited (ODD), a biotechnology company with a proprietary computational and machine learning platform. Alongside new investments and grant funding from the UK Department of Health and Social Care’s UK-China research competition, ODD has raised a further £2.2M. This brings their total amount of grant and equity funding to over £9M in 2019.
This new injection of capital allows ODD to advance its research, in particular, it will fund its latest projects targeting the discovery of new antibiotics and development of cutting-edge solutions that will tackle the critical issue of anti-microbial resistance in humans and animals.
Tim Mills, Investment Director of the Angel CoFund said, “The team at Oxford Drug Design are advancing swiftly with their programme, and winning major international funding and attracting private equity funding provide strong validation of the work they are undertaking. Antimicrobial resistance is a growing issue for the global healthcare system which only a small number of innovative companies are working to solve, so we are delighted to support ODD’s pioneering efforts.”
Paul Finn, CEO of Oxford Drug Design said, “This latest funding further validates our computational design-led focus that has enabled rapid progress in building our pipeline of novel antibiotic programmes. We are excited to be working with partners in the UK and China to develop a novel solution to the major challenge of supporting animal health without contributing to the rise of anti-microbial resistance in human infections, with potential benefits for food production and human health worldwide.”
Source: Oxford Drug Design